Paving the road to MRD-guided treatment in CLL

Abstract

In this issue of Blood, Strati et al provide evidence suggesting that the efficacy of chemoimmunotherapy is maintained in chronic lymphocytic leukemia (CLL) patients who received only 3 treatment cycles but nevertheless attained minimal residual disease (MRD) negativity.1 © 2014 by The American Society of Hematology.